Executive Summary

The cost of late resolution extends beyond the technical fix. It includes the capital, timelines, partnerships, and expectations built around unresolved manufacturing uncertainty. An issue addressed early may remain manageable; the same issue discovered after major commitments have formed can become an enterprise event.

The Phase 2 Manufacturing Wall™ explains how a readiness–exposure gap forms. The Cost of Late Resolution™ examines what that gap costs. As development advances, Enterprise Exposure can grow faster than Demonstrated Readiness. When assumptions prove incomplete, the consequences spread beyond manufacturing into financing, clinical timelines, strategic choices, and asset value.

The decisive question is: What enterprise exposure is being created while critical manufacturing uncertainty remains unresolved?

Six Mechanisms of Enterprise Cost

Schedule Compression
Manufacturing delays propagate into clinical supply, enrollment, regulatory submissions, and milestone timing. The enterprise cost depends on the activities disrupted and the value of the time lost.

Capital Compression
Additional technical work consumes cash while delays extend operating burn. Financing may become necessary before the next value milestone, with less runway and weaker negotiating leverage.

Optionality Loss
Processes, suppliers, formulations, and timelines are easier to change before commitments harden. Contracts, transfers, filings, and capacity decisions can make the same response substantially more expensive later.

Organizational Distortion
Technical teams and senior leaders shift from advancing the program to managing recovery. Investigations, replanning, stakeholder communication, and confidence rebuilding consume attention otherwise available for value creation.

Commercial Value Erosion
Delays approaching commercialization can narrow the effective patent runway, weaken competitive position, and forfeit launch opportunities. Some lost value does not return when the technical issue is resolved.

Valuation Fragility
Manufacturing assumptions can remain implicit while clinical progress builds confidence. When previously unrecognized fragility becomes visible, the program may face abrupt repricing.

These mechanisms can compound. Their magnitude is program-specific; the framework does not assign a universal dollar cost or predictive coefficient.

The Readiness Premium™

Earlier resolution preserves value by protecting critical timelines, retaining strategic options, and reducing exposure to avoidable disruption. Readiness does not require eliminating every uncertainty. It requires enough evidence to support the next commitment—and a clear understanding of what remains unresolved.

Read the Full White Paper

Download The Cost of Late Resolution™ for the complete framework, worked scenario, historical cases, and implications for executive teams, boards, and investors.

From Framework to Program Decisions

Discuss how your program’s demonstrated readiness compares with its accumulating enterprise exposure. Portfolio CMC Advisors helps teams identify manufacturing uncertainty, examine its implications, and prioritize the evidence needed before the next major commitment.

Start an advisory conversation with Portfolio CMC Advisors.